Parkinson’s Disease: Physiopathologic and Therapeutic Aspects

Detalhes bibliográficos
Autor(a) principal: Ferreira, Flavio Dias
Data de Publicação: 2010
Outros Autores: Ferreira, Francine Maery Dias, Heleno, Raquel Balestri, Mella Júnior, Sidney Edson
Tipo de documento: Artigo
Idioma: por
Título da fonte: Saúde e Pesquisa (Online)
Texto Completo: https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353
Resumo: The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible.
id CESUMAR-1_ee1e2fa621d1b7ed0f046fff7e663ecd
oai_identifier_str oai:ojs.pkp.sfu.ca:article/1353
network_acronym_str CESUMAR-1
network_name_str Saúde e Pesquisa (Online)
repository_id_str
spelling Parkinson’s Disease: Physiopathologic and Therapeutic AspectsDoença de Parkinson: Aspectos Fisiopatológicos e TerapêuticosAntiparkinsonianParkinson's diseaseLevodopa.AntiparkinsonianosDoença de ParkinsonLevodopa.The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible.A Doença de Parkinson (DP) é uma das afecções degenerativas do sistema nervoso central mais frequentes, de caráter progressivo, que acomete núcleos de base. Clinicamente, caracteriza-se por tremor de repouso, rigidez muscular e bradicinesia. Com a progressão da doença, o paciente tem limitação gradativa dessa independência com prejuízos para sua autonomia. Os comprometimentos físico-mental, emocional, social e econômico associados aos sinais e sintomas e às complicações secundárias da DP interferem no nível de incapacidade do indivíduo e podem influenciar negativamente a qualidade de vida do mesmo. A levodopa é o precursor metabólico da dopamina e isoladamente o fármaco mais eficaz para o tratamento da DP. Na prática, o uso deste fármaco é associado à Carbidopa ou Benserazida, pois administrada isoladamente ela é em grande parte descarboxilada. O uso da desta alivia alguns dos sintomas relacionados à parte motora da DP. A pesquisa bibliográfica foi realizada em sites indexadores e alguns livros referente ao assunto. A presente revisão torna mais claro que a evolução da doença é variável, pois os pacientes podem permanecer muitos anos com os mesmo sintomas e pouco incapacitados ao lado de outros cuja progressão é mais rápida. O que se deve manter claro é que, com os recursos terapêuticos disponíveis, na maioria dos casos, é possível manter o paciente em condições clínicas que permitam, por longos períodos, um nível de vida normal ou próximo a este, embora uma cura radical, definitiva, ainda não seja possível.Universidade Cesumar - UniCesumar2010-05-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de Literaturaapplication/pdfhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353Saúde e Pesquisa; Vol 3 No 2 (2010): maio/ago.Saúde e Pesquisa; v. 3 n. 2 (2010): maio/ago.2176-9206reponame:Saúde e Pesquisa (Online)instname:Cesumar Diretoria de Pesquisainstacron:CESUMARporhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353/1080Ferreira, Flavio DiasFerreira, Francine Maery DiasHeleno, Raquel BalestriMella Júnior, Sidney Edsoninfo:eu-repo/semantics/openAccess2022-05-23T16:28:11Zoai:ojs.pkp.sfu.ca:article/1353Revistahttps://periodicos.unicesumar.edu.br/index.php/saudpesqPUBhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/oainaep@cesumar.br2176-92061983-1870opendoar:2022-05-23T16:28:11Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisafalse
dc.title.none.fl_str_mv Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
Doença de Parkinson: Aspectos Fisiopatológicos e Terapêuticos
title Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
spellingShingle Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
Ferreira, Flavio Dias
Antiparkinsonian
Parkinson's disease
Levodopa.
Antiparkinsonianos
Doença de Parkinson
Levodopa.
title_short Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
title_full Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
title_fullStr Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
title_full_unstemmed Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
title_sort Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
author Ferreira, Flavio Dias
author_facet Ferreira, Flavio Dias
Ferreira, Francine Maery Dias
Heleno, Raquel Balestri
Mella Júnior, Sidney Edson
author_role author
author2 Ferreira, Francine Maery Dias
Heleno, Raquel Balestri
Mella Júnior, Sidney Edson
author2_role author
author
author
dc.contributor.author.fl_str_mv Ferreira, Flavio Dias
Ferreira, Francine Maery Dias
Heleno, Raquel Balestri
Mella Júnior, Sidney Edson
dc.subject.por.fl_str_mv Antiparkinsonian
Parkinson's disease
Levodopa.
Antiparkinsonianos
Doença de Parkinson
Levodopa.
topic Antiparkinsonian
Parkinson's disease
Levodopa.
Antiparkinsonianos
Doença de Parkinson
Levodopa.
description The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible.
publishDate 2010
dc.date.none.fl_str_mv 2010-05-18
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de Literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353
url https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353/1080
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Cesumar - UniCesumar
publisher.none.fl_str_mv Universidade Cesumar - UniCesumar
dc.source.none.fl_str_mv Saúde e Pesquisa; Vol 3 No 2 (2010): maio/ago.
Saúde e Pesquisa; v. 3 n. 2 (2010): maio/ago.
2176-9206
reponame:Saúde e Pesquisa (Online)
instname:Cesumar Diretoria de Pesquisa
instacron:CESUMAR
instname_str Cesumar Diretoria de Pesquisa
instacron_str CESUMAR
institution CESUMAR
reponame_str Saúde e Pesquisa (Online)
collection Saúde e Pesquisa (Online)
repository.name.fl_str_mv Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisa
repository.mail.fl_str_mv naep@cesumar.br
_version_ 1754122531983327232